The Dual Role of B Cells in the Tumor Microenvironment: Implications for Cancer Immunology and Therapy

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Nov 9

PMID 39519376

Authors

Hao Yang

Zhiru Zhang

Jijun Li

Kun Wang

Wanting Zhu

Yingyue Zeng

Affiliations

Soon will be listed here.

Abstract

The tumor microenvironment (TME) is a complex and heterogeneous tissue composed of various cell types, including tumor cells, stromal cells, and immune cells, as well as non-cellular elements. Given their pivotal role in humoral immunity, B cells have emerged as promising targets for anti-tumor therapies. The dual nature of B cells, exhibiting both tumor-suppressive and tumor-promoting functions, has garnered significant attention. Understanding the distinct effects of various B cell subsets on different tumors could pave the way for novel targeted tumor therapies. This review provides a comprehensive overview of the heterogeneous B cell subsets and their multifaceted roles in tumorigenesis, as well as the therapeutic potential of targeting B cells in cancer treatment. To develop more effective cancer immunotherapies, it is essential to decipher the heterogeneity of B cells and their roles in shaping the TME.

Citing Articles

Identification of B Cell Subpopulations with Pro- and Anti-Tumorigenic Properties in an Immunocompetent Mouse Model of Head and Neck Squamous Cell Carcinoma.

Sonntag M, Stanojevic S, Laban S, Schuler P, Hoffmann T, Brunner C Cells. 2025; 14(1.

PMID: 39791721 PMC: 11720715. DOI: 10.3390/cells14010020.

Microbiome Differences in Colorectal Cancer Patients and Healthy Individuals: Implications for Vaccine Antigen Discovery.

Ibeanu G, Rowaiye A, Okoli J, Eze D Immunotargets Ther. 2024; 13:749-774.

PMID: 39698218 PMC: 11652712. DOI: 10.2147/ITT.S486731.

References

Pieper K, Grimbacher B, Eibel H . B-cell biology and development. J Allergy Clin Immunol. 2013; 131(4):959-71. DOI: 10.1016/j.jaci.2013.01.046. View

Lutz E, Wu A, Bigelow E, Sharma R, Mo G, Soares K . Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res. 2014; 2(7):616-31. PMC: 4082460. DOI: 10.1158/2326-6066.CIR-14-0027. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Nemazee D, Weigert M . Revising B cell receptors. J Exp Med. 2000; 191(11):1813-7. PMC: 2213535. DOI: 10.1084/jem.191.11.1813. View

Lee K, Spata M, Bayne L, Buza E, Durham A, Allman D . Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia. Cancer Discov. 2015; 6(3):256-69. PMC: 4783189. DOI: 10.1158/2159-8290.CD-15-0822. View

Oh J, Iijima N, Song E, Lu P, Klein J, Jiang R . Migrant memory B cells secrete luminal antibody in the vagina. Nature. 2019; 571(7763):122-126. PMC: 6609483. DOI: 10.1038/s41586-019-1285-1. View

Katoh H, Komura D, Konishi H, Suzuki R, Yamamoto A, Kakiuchi M . Immunogenetic Profiling for Gastric Cancers Identifies Sulfated Glycosaminoglycans as Major and Functional B Cell Antigens in Human Malignancies. Cell Rep. 2017; 20(5):1073-1087. DOI: 10.1016/j.celrep.2017.07.016. View

Yang Z, Wang W, Zhao L, Wang X, Gimple R, Xu L . Plasma cells shape the mesenchymal identity of ovarian cancers through transfer of exosome-derived microRNAs. Sci Adv. 2021; 7(9). PMC: 7904265. DOI: 10.1126/sciadv.abb0737. View

Sharonov G, Serebrovskaya E, Yuzhakova D, Britanova O, Chudakov D . B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nat Rev Immunol. 2020; 20(5):294-307. DOI: 10.1038/s41577-019-0257-x. View

10.

Sagiv-Barfi I, Kohrt H, Czerwinski D, Ng P, Chang B, Levy R . Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A. 2015; 112(9):E966-72. PMC: 4352777. DOI: 10.1073/pnas.1500712112. View

11.

Hong S, Zhang Z, Liu H, Tian M, Zhu X, Zhang Z . B Cells Are the Dominant Antigen-Presenting Cells that Activate Naive CD4 T Cells upon Immunization with a Virus-Derived Nanoparticle Antigen. Immunity. 2018; 49(4):695-708.e4. DOI: 10.1016/j.immuni.2018.08.012. View

12.

Liu K, Cui J, Zhan Y, Ouyang Q, Lu Q, Yang D . Reprogramming the tumor microenvironment by genome editing for precision cancer therapy. Mol Cancer. 2022; 21(1):98. PMC: 8996591. DOI: 10.1186/s12943-022-01561-5. View

13.

Griss J, Bauer W, Wagner C, Simon M, Chen M, Grabmeier-Pfistershammer K . B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat Commun. 2019; 10(1):4186. PMC: 6744450. DOI: 10.1038/s41467-019-12160-2. View

14.

Wu H, Xia L, Jia D, Zou H, Jin G, Qian W . PD-L1 regulatory B cells act as a T cell suppressor in a PD-L1-dependent manner in melanoma patients with bone metastasis. Mol Immunol. 2020; 119:83-91. DOI: 10.1016/j.molimm.2020.01.008. View

15.

Shalapour S, Lin X, Bastian I, Brain J, Burt A, Aksenov A . Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature. 2017; 551(7680):340-345. PMC: 5884449. DOI: 10.1038/nature24302. View

16.

Kim S, Shen S, Miyauchi S, Sanders P, Franiak-Pietryga I, Mell L . B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade. Clin Cancer Res. 2020; 26(13):3345-3359. PMC: 7334097. DOI: 10.1158/1078-0432.CCR-19-3211. View

17.

Elhanani O, Ben-Uri R, Keren L . Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell. 2023; 41(3):404-420. DOI: 10.1016/j.ccell.2023.01.010. View

18.

Weiner A, Vidotto T, Liu Y, Mendes A, Salles D, Faisal F . Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. Nat Commun. 2021; 12(1):935. PMC: 7876147. DOI: 10.1038/s41467-021-21245-w. View

19.

Bruno T, Ebner P, Moore B, Squalls O, Waugh K, Eruslanov E . Antigen-Presenting Intratumoral B Cells Affect CD4 TIL Phenotypes in Non-Small Cell Lung Cancer Patients. Cancer Immunol Res. 2017; 5(10):898-907. PMC: 5788174. DOI: 10.1158/2326-6066.CIR-17-0075. View

20.

Wennhold K, Weber T, Klein-Gonzalez N, Thelen M, Garcia-Marquez M, Chakupurakal G . CD40-activated B cells induce anti-tumor immunity in vivo. Oncotarget. 2016; 8(17):27740-27753. PMC: 5438605. DOI: 10.18632/oncotarget.7720. View